Literature DB >> 2565604

The neu (c-erbB-2) oncogene.

H C Maguire1, M I Greene.   

Abstract

The neu gene was first identified in rat tumors that had been induced by the carcinogen ethyl nitrosourea. The human homolog of neu, usually designated c-erbB-2, is located on chromosome 17, q21. It specifies a transmembrane receptor-like phosphoglycoprotein that is closely related to the EGFr (c-erbB-1). The ligand for c-erbB-2 is not known. A significant proportion of adenocarcinomas (especially of the breast, colon, and pancreas) have amplification and/or overexpression of c-erbB-2. The unique qualities associated with the subset of tumors that overexpress c-erbB-2 have not yet been firmly identified.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565604

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  19 in total

1.  Asymmetric distribution of oncogene products at mitosis.

Authors:  B Czerniak; F Herz; R P Wersto; L G Koss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

2.  Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays.

Authors:  Katrin Tiemann; Carolina Garri; Jeffrey Wang; Lauren Clarke; Kian Kani
Journal:  J Vis Exp       Date:  2018-09-19       Impact factor: 1.355

3.  An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.

Authors:  Judith Staerk; Catherine Lacout; Takeshi Sato; Steven O Smith; William Vainchenker; Stefan N Constantinescu
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

Review 4.  Immunologic approaches to inhibiting cell-surface-residing oncoproteins in human tumors.

Authors:  D M O'Rourke; M I Greene
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

5.  Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.

Authors:  Nikki Cheng; Neil A Bhowmick; Anna Chytil; Agnieszka E Gorksa; Kimberly A Brown; Rebecca Muraoka; Carlos L Arteaga; Eric G Neilson; Simon W Hayward; Harold L Moses
Journal:  Oncogene       Date:  2005-07-28       Impact factor: 9.867

6.  Analysis of c-erbB2 protein content of human glioma cells and tumor tissue.

Authors:  H H Engelhard; M Wolters; P S Criswell
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer.

Authors:  Sun-Young Kong; Do Hoon Lee; Eun Sook Lee; Susan Park; Keun Seok Lee; Jungsil Ro
Journal:  Cancer Res Treat       Date:  2006-02-28       Impact factor: 4.679

8.  Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma.

Authors:  H Schimmelpenning; E T Eriksson; U G Falkmer; E Azavedo; G Svane; G U Auer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

9.  c-fos oncogene underexpression in salivary gland tumors as measured by in situ hybridization.

Authors:  C Birek; E Lui; I Dardick
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

10.  Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors.

Authors:  D Chatterjee; C J Liu; D Northey; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.